Olympus削减利润预测,由于销售下滑、关税、召回和林业发展局的检查,导致11%的股份下降。 Olympus cut profit forecast, sparking 11% share drop due to sales slump, tariffs, recalls, and FDA scrutiny.

奥林匹斯股票在东京早期贸易中下跌了11%,这是自2025年6月以来最大幅度的下降,因为该公司将其全年营业收入预测削减到75亿至870亿日元,远远低于1 330亿日元的共识。 Olympus shares dropped as much as 11% in early Tokyo trading, their steepest decline since June 2025, after the company cut its full-year operating income forecast to ¥75–87 billion, well below the ¥132 billion consensus. 该修订案列举了在外科手术干预业务中持续暂停装运、销售疲软、费用增加、美国关税和自愿召回产品。 The revision cited ongoing shipment suspensions in its surgical intervention business, weaker sales, higher costs, U.S. tariffs, and a voluntary product recall. 第三季度的营业利润下降了37%,降至240亿日元,未达到预期值。 Third-quarter operating profit fell 37% to ¥24 billion, missing expectations. 下降的原因是林业发展局对某些日本制造的装置进行了检查,并在CEO Bob White领导下不断进行结构调整。 Bob White正在削减2 000个工作岗位,转而采用全球效率模式,包括在印度建立一个新的研发枢纽。 The decline follows FDA scrutiny of certain Japanese-made devices and ongoing restructuring under CEO Bob White, who is cutting 2,000 jobs and shifting to a global efficiency model, including a new R&D hub in India.